Effect of Guiluxian on the outcome of in vitro fertilization and embryo transfer in elderly women with low prognosis: a multicenter, double-blind, randomized, placebo-controlled trial

注册号:

Registration number:

ITMCTR1900002843

最近更新日期:

Date of Last Refreshed on:

2019-12-16

注册时间:

Date of Registration:

2019-12-16

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

龟鹿仙对高龄低预后女性体外受精-胚胎移植结局的影响:一项多中心、双盲、随机、安慰剂对照试验

Public title:

Effect of Guiluxian on the outcome of in vitro fertilization and embryo transfer in elderly women with low prognosis: a multicenter, double-blind, randomized, placebo-controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

龟鹿仙对高龄低预后女性体外受精-胚胎移植结局的影响:一项多中心、双盲、随机、安慰剂对照试验

Scientific title:

Effect of Guiluxian on the outcome of in vitro fertilization and embryo transfer in elderly women with low prognosis: a multicenter, double-blind, randomized, placebo-controlled trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900028255 ; ChiMCTR1900002843

申请注册联系人:

马英杰

研究负责人:

孙振高

Applicant:

MA Yingjie

Study leader:

Sun Zhengao

申请注册联系人电话:

Applicant telephone:

+86 17862968525

研究负责人电话:

Study leader's telephone:

+86 13708938621

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

545914553@qq.com

研究负责人电子邮件:

Study leader's E-mail:

sunzhengao77@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

山东省济南市文化西路42号

研究负责人通讯地址:

山东省济南市文化西路42号

Applicant address:

42 Wenhua Road West, Lixia District, Ji'nan, Shandong, China

Study leader's address:

42 Wenhua Road West, Lixia District, Ji'nan, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东中医药大学第一临床医学院

Applicant's institution:

The First Clinical Medical College of Shandong University of traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东中医药大学附属医院

Primary sponsor:

Affiliated Hospital of Shandong University of traditional Chinese Medicine

研究实施负责(组长)单位地址:

山东省济南市文化西路42号

Primary sponsor's address:

42 Wenhua Road West, Lixia District, Ji'nan, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学附属医院

具体地址:

文化西路42号山东中医药大学附属医院西院区

Institution
hospital:

Affiliated Hospital of Shandong University of traditional Chinese Medicine

Address:

42 Wenhua Road West

经费或物资来源:

山东中医药大学附属医院

Source(s) of funding:

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

研究疾病:

高龄低预后不孕患者

研究疾病代码:

Target disease:

Infertile patients with advanced age and low prognosis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

龟鹿仙对高龄低预后女性体外受精-胚胎移植结局的影响。

Objectives of Study:

Effect of tortoise deer fairy on the outcome of in vitro fertilization and embryo transfer in elderly women with low prognosis.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

本研究将招募年龄35-42岁、符合西医不孕症诊断标准、卵巢储备参数(AFC<5、AMH<1.1ng/mL、FSH≥10IU/L)不足、卵巢反应较差(即标准卵巢刺激后获得的卵母细胞≤3 个)、符合IVF-ET适应症的受试者。

Inclusion criteria

In this study, we will recruit subjects who are 35 and 42 years old, meet the diagnostic criteria of western medicine infertility, insufficient ovarian reserve parameters (AFC < 5, AMH < 1.1ng/mL, FSH >= 10IU / L), poor ovarian response (i.e. oocytes obtained after standard ovarian stimulation <= 3), and meet the indications of IVF-ET.

排除标准:

(1)BMI≥25Kg/m2; (2)患有《母婴保健法》中规定的不适合生育的遗传性疾病者; (3)重度子宫内膜异位症、子宫腺肌病,免疫性不育; (4)未处理的输卵管积水; (5)先天性或后天性子宫发育异常及其他生殖器官严重畸形; (6)合并生殖系统肿瘤、甲状腺功能异常、高泌乳素血症等内分泌功能障碍史; (7)近三月接受卵巢刺激治疗或OCP; (8)既往无卵巢等妇科手术史; (9)男方因素(少弱畸精子症、梗阻性无精子症、隐匿性精子症等); (10)以及其他辅助生殖技术禁忌证。

Exclusion criteria:

(1) BMI >= 25Kg/m2; (2) those suffering from genetic diseases that are not suitable for reproduction as stipulated in the law on maternal and child health care; (3) severe endometriosis, adenomyosis, and immune infertility; (4) untreated hydrosalpinx; (5) congenital or acquired abnormal uterine development and other serious reproductive organ malformations; (6) complicated with reproductive system tumor, thyroid dysfunction, hyperprolactinemia and other endocrine dysfunction; (7) received ovarian stimulation treatment or OCP in recent 3 months; (8) no previous history of ovarian and other gynecological operations; (9) male factors (oligoweak teratozoospermia, obstructive azozoospermia, occult spermatozoospermia, etc.); (10) and other contraindications of assisted reproductive technology.

研究实施时间:

Study execute time:

From 2019-12-23

To      2020-03-23

征募观察对象时间:

Recruiting time:

From 2019-12-23

To      2020-06-23

干预措施:

Interventions:

组别:

对照组

样本量:

60

Group:

control group

Sample size:

干预措施:

口服安慰剂

干预措施代码:

Intervention:

Oral placebo

Intervention code:

组别:

试验组

样本量:

60

Group:

experimental group

Sample size:

干预措施:

口服龟鹿仙

干预措施代码:

Intervention:

Oral Guiluxian

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

山东省

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学附属医院

单位级别:

三级甲等医院

Institution/hospital:

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

获得卵泡数

指标类型:

主要指标

Outcome:

Obtain the number of follicles

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

卵泡液

组织:

Sample Name:

Follicular fluid

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 35
Min age years
最大 42
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

当自愿参与研究的患者加入后,采用分层区组随机的方法,按研究地点分层(N),设置区组长度为 4,区组为 N/4,根据 R 语言 version 3.5.1 生成随机数并进行区组随机化,两组受试者比例为 1:1。将治疗组与安慰剂进行编码(1001、1002、1003、 1004、1005···),与受试者编码一一对应(001、002、003、004、005···)

Randomization Procedure (please state who generates the random number sequence and by what method):

When the volunteers participated in the study, the method of stratified block randomization was used. According to the location of the study, the (N), set the block length to 4 and the block to Nmax 4. According to the R language version 3.5.1, the random number was generated and randomized. The&#32

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开原始数据日期(2020-06-26)和方式(发表文章); ResMan, http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Date and manner of publishing raw data (2020-06-26) ; ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表(Case Record Form, CRF)方式记录,定期按照计划书上传

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form (CRF) was used to record and upload regularly according to the plan.

数据管理委员会:

Data Managemen Committee:

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above